ALXO compared with ARTV: revenue, margins and what each company keeps, and the suppliers and customers both name

ALXOALX Oncology Holdings Inc

Mkt capRevenueRevenue

ARTVArtiva Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

ALXOALX Oncology Holdings Inc

ARTVArtiva Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ALXO1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±51.4%▲+9.90%×0.19

ARTV2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Oct 27 '26±76.2%▼−30.68%×0.40

Q2 FY26±35.1%▼−2.68%×0.08

= impliedALXO realized, solidARTV realized, hatchedOne scale, both sides: full bar = 77%× = |realized| ÷ impliedSource: market data

ALXOALX Oncology Holdings Inc

1.15▲+0.07%· post 1.15

Mkt cap$159.7MRevenue—

ARTVArtiva Biotherapeutics, Inc.

4.16▲+0.61%· post 4.16

ClosedNov 6 '26

Mkt cap$202.9MRevenue$251,000Q1 FY24

Compare

ClosedNov 6 '26

ALXOALX Oncology Holdings Inc

ARTVArtiva Biotherapeutics, Inc.

1.15▲+0.07%post 1.15

Price

4.16▲+0.61%post 4.16

$159.7M

Mkt cap

$202.9M

—

Revenue

$251,000Q1 FY24

ALXO1.15▲+0.07%vsARTV4.16▲+0.61%ClosedNov 6 '26